Education
About Us
Working with TipRanks
Follow Us
Immuneering (IMRX)
NASDAQ:IMRX
Total Valuation
Immuneering has a market cap or net worth of $381.61M. The enterprise value is $54.04M.
Market Cap$381.61M
Enterprise Value$54.04M
Share Statistics
Immuneering has 64,569,970 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding64,569,970
Owned by Insiders9.41%
Owned by Institutions13.36%
Financial Efficiency
Immuneering’s return on equity (ROE) is -1.47 and return on invested capital (ROIC) is -139.63%.
Return on Equity (ROE)-1.47
Return on Assets (ROA)-1.16
Return on Invested Capital (ROIC)-139.63%
Return on Capital Employed (ROCE)-1.42
Revenue Per Employee0.00
Profits Per Employee-1.13M
Employee Count54
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Immuneering is ―. Immuneering’s PEG ratio is -0.13.
PE Ratio―
PS Ratio0.00
PB Ratio1.59
Price to Fair Value1.59
Price to FCF-1.20
Price to Operating Cash Flow-5.20
PEG Ratio-0.13
Income Statement
In the last 12 months, Immuneering had revenue of 0.00 and earned -61.04M in profits. Earnings per share was -2.04.
Revenue0.00
Gross Profit0.00
Operating Income-64.07M
Pretax Income-61.04M
Net Income-61.04M
EBITDA-63.69M
Earnings Per Share (EPS)-2.04
Cash Flow
In the last 12 months, operating cash flow was -50.01M and capital expenditures -27.67K, giving a free cash flow of -50.04M billion.
Operating Cash Flow-50.01M
Free Cash Flow-50.04M
Free Cash Flow per Share-0.78
Dividends & Yields
Immuneering pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.22
52-Week Price Change184.00%
50-Day Moving Average6.42
200-Day Moving Average4.20
Relative Strength Index (RSI)51.44
Average Volume (3m)1.27M
Important Dates
Immuneering upcoming earnings date is Mar 11, 2026, Before Open (Confirmed).
Last Earnings DateNov 12, 2025
Next Earnings DateMar 11, 2026
Ex-Dividend Date―
Financial Position
Immuneering as a current ratio of 5.28, with Debt / Equity ratio of 13.83%
Current Ratio5.28
Quick Ratio5.28
Debt to Market Cap<0.01
Net Debt to EBITDA0.50
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Immuneering has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Immuneering EV to EBITDA ratio is -0.53, with an EV/FCF ratio of -0.62.
EV to Sales0.00
EV to EBITDA-0.53
EV to Free Cash Flow-0.62
EV to Operating Cash Flow-0.62
Balance Sheet
Immuneering has $227.56M in cash and marketable securities with $3.92M in debt, giving a net cash position of $223.65M billion.
Cash & Marketable Securities$227.56M
Total Debt$3.92M
Net Cash$223.65M
Net Cash Per Share$3.46
Tangible Book Value Per Share$1.15
Margins
Gross margin is -11.03%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-11.03%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Immuneering is $16.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$16.67
Price Target Upside160.88% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast9.32%